83-5980-95 eIF4E (Eukaryotic Translation Initiation Factor 4E, eIF-4E, eIF-4F 25 kD Subunit, mRNA Cap-binding Protein) 100ug 052031

※お見積書はカートで印刷できます

冷凍

特徴

  • The initiation step of protein translation requires a number of eukaryotic translation initiation factors (eIFs).
  • Initially, the 40S ribosomal subunit associates with Met-tRNAi and a group of initiation factors, including eIF1, eIF1A, eIF2, eIF3, and eIF5 to form the 43S pre-initiation complex.
  • This complex is then recruited to the 5'-end of capped mRNA by another complex of factors (known as eIF4F) consisting of eIF4E, eIF4G, and eIF4A.
  • eIF4E is an indispensable element for cap-dependent translation initiation and plays a major role in recognition of the mRNA cap structure.
  • It binds to eIF4G, which serves as a scaffolding protein to gather eIF4A (ATP-dependent RNA helicase), eIF4B, eIF3, and poly-A-binding protein to form the 48S complex.
  • This complex then scans the mRNA for an initiation codon and, once this is located, the 60S ribosomal subunit joins to form the elongation-competent fully functional 80S.
  • eIF4E is the least abundant of the cellular translation initiation components and it represents the rate-limiting element for the initiation process.
  • Under resting conditions, eIF4E is kept in an inactive form bound to 4E-binding proteins (4E-BPs); once the latter have been phosphorylated through the PI3K-AKT-mTOR signaling pathway, eIF4E is released and binds eIF4G to launch translation.
  • eIF4E is upregulated in various human tumors, and it contributes to transformation, tumorigenesis, and cancer progression.
  • eIF4E overexpression facilitates translation of weak and highly structured mRNAs that typically encode proteins involved in cancer biology, such as proto-oncoproteins (e.g.
  • cyclin D1, ornithine decarboxylase), angiogenesis factors (e.g.
  • FGF-2, VEGF), and factors related to tumor invasiveness, such as MMP-9.
  • Therefore, eIF4E serves as an attractive cancer drug target.
  • Applications:Suitable for use in Western Blot and Immunocytochemistry.
  • Other applications not tested.
  • Recommended Dilution:Western Blot: 0.1-1ug/mlImmunocytochemistry: 0.2-2ug/mlOptimal dilutions to be determined by the researcher.
  • Storage and Stability:May be stored at 4℃ for short-term only.
  • Aliquot to avoid repeated freezing and thawing.
  • Store at -20℃.
  • Aliquots are stable for 12 months after receipt.
  • For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

仕様

  • Size:100ug
  • 抗体種類:Mab
  • 宿主:mouse
  • Source Antibody:human
  • Grade:Affinity Purified
  • Purity:Purified by affinity chromatography.
  • Form:Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
  • Specificity:Recognizes human eIF4E. Does not cross-react with mouse
  • Clone # USB:P85D11B4
  • Isotype:IgG2a,k
  • Calc Applications Abbrev:IC WB
  • Calc Crossreactivity:Hu
  • Immunogen:Purified full length recombinant protein corresponding to aa1-217 from human eIF4E, expressed in E. coli.
  • Swiss Prot Number:P06730
  • EU Commodity Code:30021010
  • この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
  • 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
  • 【試薬に関するお問合せ】
  • アズワン株式会社 試薬・プロセス材料グループ
  • TEL:06-6447-8641
  • FAX:06-6447-8642
  • E-mail:[email protected]
アズワン品番
83-5980-95
型番
052031
入り数
1個
標準価格
149,000円(税抜)
WEB価格
アズワン在庫 [?]
数量

※お気に入り機能はログイン後にご利用いただけます

よくあるご質問

よくあるご質問(FAQ)

掲載カタログ情報

掲載カタログ名 掲載ページ

次の商品を登録しました。

商品計:

お買い物を続ける カートを見る